Molecular diagnostic testing is a 9.2 billion dollar industry. Advancements in portable and affordable sequencers and other testing materials have facilitated numerous new testing companies. This sector is expected to grow exponentially due to the influx of new technology, the relapse and introduction of new infectious diseases, development of self- tests, and the growing demand for advanced cancer diagnostic tests and genetic testing.

Bridge Lane Global is proud to celebrate, support, and encourage diversity, difference, equal opportunity, and mutual respect and the contributions that diversity, difference, opportunity, and mutual respect make to enriching and enhancing our institution, our business, and our society. We make our decisions, including all employment decisions, based on business needs, job requirements, individual qualifications and merit, and the principle of equal opportunity for all, without regard to race, color, religion, age, national or social origin, ancestry, sex, sexual orientation, gender identity, preference, expression or orientation, disability status, genetics or genetic information, marital, civil union or other domestic partnership status, protected veteran status, or any other status protected by relevant laws and regulations. We do not and will not tolerate discrimination or harassment based upon any of the foregoing characteristics or statuses.